key: cord-0736333-ytrt68qi authors: Kumar, Saurabh; Haqqani, Haris; Wynn, Gareth; Pathak, Rajeev K.; Lipton, Jonathan; Mahajan, Rajiv; Sanders, Prashanthan; Healey, Stewart; Wilsmore, Bradley; Mariani, Justin A.; Thomas, Stuart P.; Weerasooriya, Rukshen; McGavigan, Andrew; Gould, Paul A.; Weatherley, Paul; Saad, Natasha; Cowan, Mitchell; Turnbull, Samual; Trivic, Ivana; Wong, Michael; Tonchev, Ivaylo; Morton, Joseph B.; Skinner, Jonathan R.; Pflaumer, Andreas; McGuire, Mark; Kistler, Peter; Kalman, Jonathan M. title: Position Statement on the Management of Cardiac Electrophysiology and Cardiac Implantable Electronic Devices in Australia during the COVID-19 Pandemic: A Living Document() date: 2020-05-11 journal: Heart Lung Circ DOI: 10.1016/j.hlc.2020.04.001 sha: 1444c59f6e2f0b739c509c800ef58f4f5f6402ea doc_id: 736333 cord_uid: ytrt68qi The COVID-19 pandemic poses a significant stress on health resources in Australia. The Heart Rhythm Council of the Cardiac Society of Australia and New Zealand aims to provide a framework for efficient resource utilisation balanced with competing risks when appropriately treating patients with cardiac arrhythmias. This document provides practical recommendations for the electrophysiology (EP) and cardiac implantable electronic devices (CIED) services in Australia. The document will be updated regularly as new evidence and knowledge is gained with time. vices [1] . 98 In response to this pandemic, the Cardiac Society of 99 Australia and New Zealand (CSANZ) Board requested the 100 Heart Rhythm Council rapidly produce a ''live" document to 101 provide guidance to its members for the practice of EP and 102 CIED services in Australia. The document takes into account 103 published grey papers from international societies and 104 advice from key opinion leaders within Australia and over-105 seas, with frequent updates to adapt to the evolving pan-106 demic and its impact on the Australian health system. The guidelines provide a framework for implementing 108 services during the pandemic. It is noted that the practice 109 of EP and CIED management in Australia is varied amongst 110 public and private hospitals, regional and remote areas, and 111 in outreach clinics. The application of these recommenda-112 tions will therefore need to be tailored to local models of 113 service delivery. 114 In response to the CSANZ board request, the Chair of the 115 Heart Rhythm Council summoned the formation of the Heart 116 Rhythm Council COVID-19 Pandemic working group. The 117 group is formed by the authors listed in this document, 118 whose responsibility it was to contribute to the original 119 source document, and who will continue provide frequent 120 updates in six Domains: 121 1 Implementing a Framework for Altered Services. The COVID-19 pandemic poses a significant stress on health resources in Australia. The Heart Rhythm Council of the Cardiac Society of Australia and New Zealand aims to provide a framework for efficient resource utilisation balanced with competing risks when appropriately treating patients with cardiac arrhythmias. This document provides practical recommendations for the electrophysiology (EP) and cardiac implantable electronic devices (CIED) services in Australia. The document will be updated regularly as new evidence and knowledge is gained with time. COVID-19 cardiac electrophysiology cardiac implantable electronic devices personal protective equipment congenital heart disease appointment. Ideally, these remote clinics will occur in a 261 location distant to areas exposed to direct patient contact. Although small studies and anecdotal reports suggest 508 that these may be useful, large scale randomised con-509 trolled data is lacking. The use of heart rate monitors (e.g. Fitbit, Garmin watch) are unlikely to be useful in this 511 setting and is discouraged. in one third of patients admitted to ICU [6] . to reduce viral load [14] . Azithromycin has anti-inflamma-798 tory effects and is an antibiotic which may cause long QT and 799 Torsade de Pointes. Case reports exist for potentiation of long 800 QT in patients with hypokalaemia and with co-administra-801 tion of other QT prolonging drugs, e.g, chloroquine [15] . Domain 4, EP and CIED Procedural Considerations: Jona-1020 than Kalman Online ahead of print Consensus 1038 guidelines for Interventional Cardiology services delivery during 1039 COVID-19 pandemic in Australia and New Zealand 1042 et al. The Heart Rhythm Society (HRS)/American Society of Anesthesi-1043 ologists (ASA) Expert Consensus Statement on the perioperative man-(STS) Random-1051 ized controlled trial of perioperative ICD management: magnet applica-1052 tion versus reprogramming Remdesivir and 1054 chloroquine effectively inhibit the recently emerged novel coronavirus 1055 (2019-nCoV) in vitro COVID-19 and the cardiovascular 1057 system Characteristics and Outcomes of 21 Critically Ill Patients With Cardiovascular complications of severe acute respiratory syndrome Case-fatality rate and characteristics of 1065 patients dying in relation to COVID-19 in Italy Online ahead of print Coronaviruses and the 1068 cardiovascular system: acute and long-term implications Online ahead of print factors for mortality of adult inpatients with COVID-19 in Wuhan, China: 1073 a retrospective cohort study Cardiovascular 1075 implications of fatal outcomes of patients with coronavirus disease COVID-19) Hydroxychloroquine and azithromycin as a treatment of COVID-19: 1083 results of an open-label non-randomized clinical trial vascular risks with azithromycin and other antibacterial drugs ance for navigating and circumventing the QTc prolonging and torsado-1090 genic potential of possible pharmacotherapies for COVID-19 Proc 2020 SARS-CoV-2 Infection in 1093 Clinical 1095 characteristics of children with coronavirus disease Clinical characteristics of novel 1098 COVID-19) in newborns, infants and children female infant infected with COVID 19: presenting with pneumonia, liver